ASH 2014: Phase II EWALL-PH-02 trial shows that nilotinib in addition to standard chemotherapy achieves remission in elderly patients with Philadelphia-positive acute lymphocytic leukaemia

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Oliver Ottmann (Goethe-University Hospital, Frankfurt, Germany) discusses a Trial of the European Working Group for Adult ALL (EWALL-PH-02), which evaluated nilotinib and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia chromosome/BCR-ABL1-positive acute lymphoblastic leukaemia.